Apotex: Amgen's Biosimilar Lawsuit's A Sham, Predatory
This article was originally published in Scrip
Executive Summary
Amgen's patent infringement lawsuit filed in August against Apotex involving its pegfilgrastim biosimilar, which is referenced on the former company's long-acting human granulocyte colony-stimulating factor Neulasta, is a "sham" and part of an "overall predatory scheme to monopolize the relevant market," the latter company charged in court documents filed this week.